Study #2025-0872
An open-label, multicenter, phase 1 trial to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma agents, in patients with relapsed or refractory non-Hodgkin lymphomas
MD Anderson Study Status
Enrolling
Treatment Agent
TLN-121, TLN-254
Description
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Lymphoma, Non Hodgkin
Study phase:
Phase I
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.